Evofem Biosciences, Inc. filed a Current Report on Form 8-K on November 13, 2026, announcing the release of its financial results for the three and nine months ended September 30, 2026.

Key Highlights

  • Reporting period: Financial results cover the three and nine months ended September 30, 2026.
  • Press release date: Evofem Biosciences issued its results press release on November 13, 2026.
  • Exhibit furnished: The press release is attached as Exhibit 99.1 and is furnished, not filed, under Section 18 of the Securities Exchange Act of 1934.
  • Signatory: The report was signed by Ivy Zhang, Chief Financial Officer of Evofem Biosciences, Inc.
  • Risk factors cited: The filing references limited cash resources and the company's ability to continue as a going concern among key risk factors.

Evofem Discloses Q3 2026 Operating Results via Press Release

Evofem Biosciences, Inc., a San Diego-based biosciences company incorporated in Delaware and headquartered at 7770 Regents Road, Suite 113-618, San Diego, CA 92122, disclosed its quarterly financial results through a press release furnished as Exhibit 99.1 to the filing. The company, which carries Commission File Number 001-36754, reported that its securities are not currently registered on any national exchange under Section 12(b) of the Act, with "None" listed in the registered securities table.

According to the filing, the information provided under Item 2.02 and in the accompanying press release "is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the registrant." The filing also references the company's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 11, 2026, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 13, 2026, as sources of additional risk disclosures.

The filing includes forward-looking statements, which the company characterizes as subject to its cautionary language. Among the risk factors disclosed, the company cited "limited cash resources," dependence on new capital or business development transactions to fund operations, reliance on third-party licensees and distributors for ex-U.S. commercialization, and risks related to the company's "limited revenue base relative to operating expenses." The company stated it undertakes no obligation to update forward-looking statements except as required by law.

What Was Disclosed

Evofem Biosciences, Inc. furnished a Current Report disclosing its financial results for the three and nine months ended September 30, 2026, via a press release dated November 13, 2026, signed by Chief Financial Officer Ivy Zhang.